| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $311,947,995 | 36 | 100 |
| McCarthy Cornelius P. III | director | 0 | $0 | 1 | $772,896 | $-772,896 |
| Kraft Robert O. | director | 0 | $0 | 1 | $3.83M | $-3.83M |
| DAVENPORT FRED B JR | director | 0 | $0 | 2 | $3.99M | $-3.99M |
| Brady Kevin M. | CFO & Treasurer | 0 | $0 | 2 | $7.22M | $-7.22M |
| EWALD STEPHEN P | General Counsel & Corp. Secy. | 0 | $0 | 2 | $10.47M | $-10.47M |
| BURWIG SUSAN E | Exec. VP, Operations | 0 | $0 | 5 | $32.46M | $-32.46M |
| GEIGER JESSE J | President | 0 | $0 | 4 | $45.61M | $-45.61M |
| Troendle August J. | CEO | 0 | $0 | 19 | $207.59M | $-207.59M |
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
Over the last 12 months, insiders at Medpace Holdings, Inc. have bought $0 and sold $311.95M worth of Medpace Holdings, Inc. stock.
On average, over the past 5 years, insiders at Medpace Holdings, Inc. have bought $86.72M and sold $393.17M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2 shares for transaction amount of $652 was made by EWALD STEPHEN P (General Counsel & Corp. Secy.) on 2025‑02‑27.
| 2025-12-03 | Sale | Troendle August J. | CEO | 668 0.0024% | $590.69 | $394,581 | -2.59% | |
| 2025-12-02 | Sale | Troendle August J. | CEO | 5,698 0.0205% | $590.47 | $3.36M | -3.78% | |
| 2025-12-01 | Sale | Troendle August J. | CEO | 23,178 0.083% | $593.25 | $13.75M | -4.48% | |
| 2025-11-28 | Sale | Troendle August J. | CEO | 15,151 0.0539% | $593.46 | $8.99M | -4.82% | |
| 2025-11-26 | Sale | Troendle August J. | CEO | 41,331 0.1468% | $606.88 | $25.08M | -6.67% | |
| 2025-11-25 | Sale | Troendle August J. | CEO | 42,392 0.1565% | $615.52 | $26.09M | -7.35% | |
| 2025-11-24 | Sale | Troendle August J. | CEO | 59,025 0.2152% | $607.78 | $35.87M | -8.23% | |
| 2025-11-24 | Sale | BURWIG SUSAN E | Exec. VP, Operations | 20,000 0.0731% | $609.15 | $12.18M | -8.23% | |
| 2025-11-21 | Sale | Troendle August J. | CEO | 21,858 0.0776% | $592.18 | $12.94M | -4.03% | |
| 2025-11-21 | Sale | Brady Kevin M. | CFO & Treasurer | 3,000 0.0106% | $590.35 | $1.77M | -4.03% | |
| 2025-11-20 | Sale | Troendle August J. | CEO | 6,830 0.0248% | $598.49 | $4.09M | -3.04% | |
| 2025-11-19 | Sale | Troendle August J. | CEO | 23,862 0.0847% | $592.07 | $14.13M | -3.98% | |
| 2025-11-18 | Sale | Troendle August J. | CEO | 7,191 0.0256% | $590.84 | $4.25M | -3.61% | |
| 2025-11-17 | Sale | Troendle August J. | CEO | 6,047 0.0217% | $591.00 | $3.57M | -2.81% | |
| 2025-11-14 | Sale | Troendle August J. | CEO | 14,747 0.0527% | $595.26 | $8.78M | -3.46% | |
| 2025-11-14 | Sale | Kraft Robert O. | director | 6,472 0.023% | $591.85 | $3.83M | -3.46% | |
| 2025-11-13 | Sale | Troendle August J. | CEO | 5,128 0.0185% | $601.37 | $3.08M | -3.63% | |
| 2025-11-12 | Sale | Troendle August J. | CEO | 5,312 0.0193% | $603.23 | $3.2M | -4.62% | |
| 2025-11-11 | Sale | BURWIG SUSAN E | Exec. VP, Operations | 18,000 0.0656% | $605.00 | $10.89M | -5.35% | |
| 2025-11-05 | Sale | GEIGER JESSE J | President | 21,503 0.0777% | $595.66 | $12.81M | -4.53% |
| Troendle August J. | CEO | 646184 2.2768% | $304.09M | 16 | 216 | +33.45% |
| BURWIG SUSAN E | Exec. VP, Operations | 27500 0.0969% | $12.94M | 2 | 15 | +3.69% |
| GEIGER JESSE J | President | 15000 0.0529% | $7.06M | 0 | 20 | |
| EWALD STEPHEN P | General Counsel & Corp. Secy. | 13343 0.047% | $6.28M | 1 | 14 | +39.73% |
| McCarthy Cornelius P. III | director | 10197 0.0359% | $4.8M | 0 | 1 | |
| Brady Kevin M. | CFO & Treasurer | 6000 0.0211% | $2.82M | 0 | 6 | |
| DAVENPORT FRED B JR | director | 3498 0.0123% | $1.65M | 1 | 2 | +12.85% |
| Kraft Robert O. | director | 833 0.0029% | $392,001.47 | 0 | 4 | |
| Medpace Investors, LLC | 10 percent owner | 4733019 16.6766% | $2.23B | 14 | 178 | +37.6% |
| Carley Brian T | director | 26032 0.0917% | $12.25M | 0 | 1 | |
| King Tom C | director | 598 0.0021% | $281,412.82 | 0 | 2 | |
| Keating Ashley M. | director | 250 0.0009% | $117,647.50 | 0 | 6 | |
| Medpace Limited Partnership | 10 percent owner | 0 0% | $0 | 0 | 6 |
| Increased Positions | 433 | +59.23% | 3M | +10.81% |
| Decreased Positions | 319 | -43.64% | 3M | -12.45% |
| New Positions | 168 | New | 358,321 | New |
| Sold Out Positions | 51 | Sold Out | 348,889 | Sold Out |
| Total Postitions | 845 | +15.6% | 24M | -1.63% |
| Blackrock, Inc. | $1.35M | 8.42% | 2.36M | -107,567 | -4.36% | 2025-09-30 |
| Vanguard Group Inc | $1.3M | 8.15% | 2.28M | -107,651 | -4.5% | 2025-09-30 |
| Aqr Capital Management Llc | $585,530.00 | 3.66% | 1.03M | +404,226 | +65.07% | 2025-09-30 |
| Wasatch Advisors Lp | $528,743.00 | 3.31% | 925,963 | -19,851 | -2.1% | 2025-09-30 |
| State Street Corp | $384,377.00 | 2.4% | 673,141 | -33,636 | -4.76% | 2025-09-30 |
| Mawer Investment Management Ltd. | $369,321.00 | 2.31% | 646,774 | -170,658 | -20.88% | 2025-09-30 |
| Geode Capital Management, Llc | $366,979.00 | 2.3% | 642,673 | +4,746 | +0.74% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $342,692.00 | 2.14% | 600,140 | +256,577 | +74.68% | 2025-09-30 |
| Baillie Gifford & Co | $333,930.00 | 2.09% | 584,796 | +62,503 | +11.97% | 2025-09-30 |
| Invesco Ltd. | $306,870.00 | 1.92% | 537,407 | +85,517 | +18.92% | 2025-09-30 |